These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 2889461)

  • 21. Famotidine and ranitidine, but not cimetidine, cause severe, disabling headache.
    Hirsch E
    Am J Gastroenterol; 1989 Feb; 84(2):202-3. PubMed ID: 2563629
    [No Abstract]   [Full Text] [Related]  

  • 22. A comparison of the influence of famotidine and cimetidine on phenytoin elimination and hepatic blood flow.
    Sambol NC; Upton RA; Chremos AN; Lin ET; Williams RL
    Br J Clin Pharmacol; 1989 Jan; 27(1):83-7. PubMed ID: 2565119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disposition of famotidine in renal insufficiency.
    Halstenson CE; Abraham PA; Opsahl JA; Chremos AN; Keane WF; Matzke GR
    J Clin Pharmacol; 1987 Oct; 27(10):782-7. PubMed ID: 3429684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Time course of inulin and creatinine clearance in the interval between two haemodialysis treatments.
    van Olden RW; van Acker BA; Koomen GC; Krediet RT; Arisz L
    Nephrol Dial Transplant; 1995 Dec; 10(12):2274-80. PubMed ID: 8808225
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Famotidine: an appraisal of its mode of action and safety.
    Berlin RG; Clineschmidt BV; Majka JA
    Am J Med; 1986 Oct; 81(4B):8-12. PubMed ID: 2877577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cimetidine versus famotidine: the effect on the pharmacokinetics of theophylline in rats.
    Mojaverian P; Rocci ML; Saccar CL; Vlasses PH; Ferguson RK
    Eur J Drug Metab Pharmacokinet; 1985; 10(2):155-9. PubMed ID: 2864251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Saturable urinary excretion kinetics of famotidine in the dog.
    Boom SP; Hoet S; Russel FG
    J Pharm Pharmacol; 1997 Mar; 49(3):288-92. PubMed ID: 9231347
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative effects of H2-receptor antagonists on drug interaction in rats.
    Lin JH; Cocchetto DM; Yeh KC; Duggan DE
    Drug Metab Dispos; 1986; 14(6):649-53. PubMed ID: 2877821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics and dynamics of famotidine in patients with renal failure.
    Gladziwa U; Klotz U; Krishna DR; Schmitt H; Glöckner WM; Mann H
    Br J Clin Pharmacol; 1988 Sep; 26(3):315-21. PubMed ID: 2902874
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure.
    Hachisu T; Yokoyama T; Oda Y; Ando K; Hattori Y; Yoshida T
    Clin Ther; 1988; 10(6):656-63. PubMed ID: 2905936
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Famotidine disposition in children and adolescents with chronic renal insufficiency.
    Maples HD; James LP; Stowe CD; Jones DP; Hak EB; Blumer JL; Vogt B; Wilson JT; Kearns GL; Wells TG;
    J Clin Pharmacol; 2003 Jan; 43(1):7-14. PubMed ID: 12520622
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A).
    Motohashi H; Uwai Y; Hiramoto K; Okuda M; Inui K
    Eur J Pharmacol; 2004 Oct; 503(1-3):25-30. PubMed ID: 15496291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety profile of H2-receptor antagonists: current status of famotidine.
    Levine JB
    J Int Med Res; 1989; 17 Suppl 1():48A-53A. PubMed ID: 2566543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of famotidine on oxidative drug metabolism.
    Somerville KW; Kitchingman GA; Langman MJ
    Eur J Clin Pharmacol; 1986; 30(3):279-81. PubMed ID: 2874031
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single-dose pharmacokinetics and bioavailability of famotidine in man. Results of multicenter collaborative studies.
    Yeh KC; Chremos AN; Lin JH; Constanzer ML; Kanovsky SM; Hucker HB; Antonello J; Vlasses P; Ryan JR; Williams RL
    Biopharm Drug Dispos; 1987; 8(6):549-60. PubMed ID: 2892544
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renal handling of enalaprilat.
    Mujais SK; Quintanilla A; Zahid M; Koch K; Shaw W; Gibson T
    Am J Kidney Dis; 1992 Feb; 19(2):121-5. PubMed ID: 1310827
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Possible famotidine-induced thrombocytopenia.
    Comer JB; Evans JA; Kerns A
    DICP; 1989 Jun; 23(6):507-8. PubMed ID: 2568035
    [No Abstract]   [Full Text] [Related]  

  • 38. H(2)-histamine antagonist (famotidine) induced adverse CNS reactions with long-standing secondary mania and epileptic seizures.
    von Einsiedel RW; Roesch-Ely D; Diebold K; Sartor K; Mundt C; Bergemann N
    Pharmacopsychiatry; 2002 Jul; 35(4):152-4. PubMed ID: 12163986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of prolonged oral cimetidine, ranitidine, and famotidine therapy on antipyrine elimination.
    Sakaue H; Akamatsu K; Hirabayashi Y; Sasaki T; Nakanishi K; Okada S; Kanaoka M; Nishinobu M; Masumoto S; Ohta Y
    Clin Ther; 1987; 9(6):602-6. PubMed ID: 2894244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical pharmacology of famotidine.
    Smith JL
    Digestion; 1985; 32 Suppl 1():15-23. PubMed ID: 2866132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.